Unit

UNIT 5.56 Monocrotaline-Induced Pulmonary Hypertension in Wistar Rats

  1. Markus Rey,
  2. Patrick Hess,
  3. Martine Clozel

Published Online: 1 SEP 2009

DOI: 10.1002/0471141755.ph0556s46

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Rey, M., Hess, P. and Clozel, M. 2009. Monocrotaline-Induced Pulmonary Hypertension in Wistar Rats. Current Protocols in Pharmacology. 46:5.56:5.56.1–5.56.11.

Author Information

  1. Actelion Pharmaceuticals, Allschwil, Switzerland

Publication History

  1. Published Online: 1 SEP 2009
  2. Published Print: SEP 2009

Abstract

Pulmonary arterial hypertension (PAH) is a debilitating and often fatal disease characterized by a progressive increase in pulmonary vascular resistance that leads to right ventricular failure. Described in this unit is an in vivo model of monocrotaline-induced pulmonary hypertension in rats that can be used to assess the effects of antihypertensive agents on pulmonary artery pressure and right ventricular hypertrophy. Curr. Protoc. Pharmacol. 46:5.56.1-5.56.11. © 2009 by John Wiley & Sons, Inc.

Keywords:

  • cardiac output;
  • hemodynamic parameters;
  • monocrotaline;
  • pulmonary hypertension;
  • rat